 |
|
|
| |
No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 8 Weeks in DAA-Naïve Patients:
an Integrated Resistance Analysis of the POLARIS-2 and POLARIS-3 Studies
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-21 Amsterdam, Netherlands
David Wyles,1 Alexander Thompson,2 Eric Lawitz,3 Bernard Willems,4 Edward J. Gane,5 Evguenia S. Svarovskaia,6 Hadas Dvory-Sobol,6 Ross Martin,6 Gregory Camus,6 Brian P. Doehle,6 Luisa M. Stamm,6 Robert H. Hyland,6 Diana M. Brainard,6 Hongmei Mo,6 Tarik Asselah,7 Ira M. Jacobson,8 Graham R. Foster,9 Stuart K. Roberts10
1UC San Diego, La Jolla, California, USA; 2St. Vincent's Hospital, Melbourne, Victoria, Australia; 3Texas Liver Institute, The University of Texas Health Science Center at San Antonio, USA; 4Centre Hospitalier de l'Universite de Montreal, Quebec, Canada; 5Auckland Clinical Studies, Auckland, New Zealand; 6Gilead Sciences, Inc., Foster City, California; 7Hopital Beaujon, Universite Paris Diderot, Clichy, France; 8Mount Sinai Beth Israel, New York, New York, USA; 9The Royal London Hospital, London, UK; 10The Alfred, Melbourne
AASLD: A Randomized, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study - (11/15/16)
AASLD: A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study - (11/15/16)
|
| |
|
|
|
|
|
